DOI QR코드

DOI QR Code

CYP1A1 (Ile462Val), CYP1B1 (Ala119Ser and Val432Leu), GSTM1 (null), and GSTT1 (null) Polymorphisms and Bladder Cancer Risk in a Turkish Population

  • Berber, Ufuk (Pathology Department, Haydarpasa Training Hospital, Gulhane Military Medical Academy) ;
  • Yilmaz, Ismail (Pathology Department, Haydarpasa Training Hospital, Gulhane Military Medical Academy) ;
  • Yilmaz, Omer (Urology Department, Haydarpasa Training Hospital, Gulhane Military Medical Academy) ;
  • Haholu, Aptullah (Pathology Department, Haydarpasa Training Hospital, Gulhane Military Medical Academy) ;
  • Kucukodaci, Zafer (Pathology Department, Haydarpasa Training Hospital, Gulhane Military Medical Academy) ;
  • Ates, Ferhat (Urology Department, Haydarpasa Training Hospital, Gulhane Military Medical Academy) ;
  • Demirel, Dilaver (Pathology Department, Haydarpasa Training Hospital, Gulhane Military Medical Academy)
  • Published : 2013.06.30

Abstract

We aimed to investigate bladder cancer risk with reference to polymorphic variants of cytochrome p450 (CYP) 1A1, CYP1B1, glutathione S-transferase (GST) M1, and GSTT1 genes in a case control study. Polymorphisms were examined in 114 bladder cancer patients and 114 age and sex-matched cancer-free subjects. Genotypes were determined using allele specific PCR for CYP1A1 and CYP1B1 genes, and by multiplex PCR and melting curve analysis for GSTM1 and GSTT1 genes. Our results revealed a statistically significant increased bladder cancer risk for GSTT1 null genotype carriers with an odds ratio of 3.06 (95% confidence interval=1.39-6.74, p=0.006). Differences of CYP1A1, CYP1B1 and GSTM1 genotype frequencies were not statistically significant between patients and controls. However, the specific combination of GSTM1 null, GSTT1 null, and CYP1B1 codon 119 risk allele carriers and specific combination of GSTM1 present, GSTT1 null, and CYP1B1 432 risk allele carriers exhibited increased cancer risk in the combined analysis. We did not observe any association between different genotype groups and prognostic tumor characteristics of bladder cancer. Our results indicate that inherited absence of GSTT1 gene may be associated with bladder cancer susceptibility, and specific combinations of GSTM1, GSTT1 and CYP1B1 gene polymorphisms may modify bladder cancer risk in the Turkish population, without any association being observed for CYP1A1 gene polymorphism and bladder cancer risk.

Keywords

Bladder cancer;CYP1A1;CYP1B1;GSTM1;GSTT1

References

  1. Aktas D, Guney I, Alikasifoglu M, et al (2002). CYP1A1 gene polymorphism and risk of epithelial ovarian neoplasm. Gynecol Oncol, 86, 124-8. https://doi.org/10.1006/gyno.2002.6720
  2. Aktas D, Hascicek M, Sozen S, et al (2004). CYP1A1 and GSTM1 polymorphic genotypes in patients with prostate cancer in a Turkish population. Cancer Gene Cytogenet, 154, 81-5. https://doi.org/10.1016/j.cancergencyto.2004.01.023
  3. Altayli E, Gunes S, Yilmaz AF, Goktas S, Bek Y (2009). CYP1A2, CYP2D6, GSTM1, GSTP1, and GSTT1 gene polymorphisms in patients with bladder cancer in a Turkish population. Int Urol Nephrol, 41, 259-66. https://doi.org/10.1007/s11255-008-9444-6
  4. Atinkaya C, Taspinar M, Sakiragaoglu S, et al (2012). The effect of CYP1A1, GSTT1 and GSTM1 polymorphisms on the risk of lung cancer: a case-control study. Hum Exp Toxicol, 31, 1074-80. https://doi.org/10.1177/0960327111428630
  5. Bartsch H, Nair U, Risch A, et al (2000). Genetic polymorphism of CYP genes, alone or in combination, as a risk modifier of tobacco-related cancers. Cancer Epidemiol Biomarkers Prev, 9, 3-28.
  6. Boffetta P, Jourenkova N, Gustavsson P (1997). Cancer risk from occupational and environmental exposure to polycyclic aromatic hydrocarbons. Cancer Causes Control, 8, 444-72. https://doi.org/10.1023/A:1018465507029
  7. Botelho MC, Machado JC, da Costa JMC (2010). Schistosoma haematobium and bladder cancer. What lies beneath? Virulence, 1, 84-7. https://doi.org/10.4161/viru.1.2.10487
  8. Cengiz M, Ozaydin A, Ozkilic AC, Dedekarginoglu G (2007). The investigation of GSTT1, GSTM1 and SOD polymorphism in bladder cancer patients. Int Urol Nephrol, 39, 1043-8. https://doi.org/10.1007/s11255-007-9179-9
  9. Dong LM, Potter JD, White E, et al (2008). Genetic susceptibility to cancer: the role of polymorphisms in candidate genes. JAMA, 299, 2423-36. https://doi.org/10.1001/jama.299.20.2423
  10. Fatima M, Garcia N, Munoz X, et al (2010). Simultaneous genotyping of GSTT1 and GSTM1 null polymorphisms by melting curve analysis in presence of SYBR Green I. J Mol Diagn, 12, 300-4. https://doi.org/10.2353/jmoldx.2010.090076
  11. Feng Z, Hu W, Rom WN, Beland FA, Tang MS (2002). 4-Aminobiphenyl is a major etiological agent of human bladder cancer: evidence from its DNA binding spectrum in human p53 gene. Carcinogenesis, 23, 1721-7. https://doi.org/10.1093/carcin/23.10.1721
  12. Hanna IH, Dawling S, Roodi N, Guengerich FP, Parl FF (2000). Cytochrome P450 1B1 (CYP1B1) pharmacogenetics: association of polymorphisms with functional differences in estrogen hydroxylation activity. Cancer Res, 60, 3440-4.
  13. Hirvonen A, Husgafvel-Pursiainen K, Karjalainen A, Anttila S, Vainio H (1992). Point-mutational MspI and Ile${\pm}$Val polymorphisms closely linked in the CYP1A1 gene: lack of association with susceptibility to lung cancer in a Finnish study population. Cancer Epidemiol Biomarkers Prev, 1, 485-9.
  14. Ji YN, Wang Q, Suo LJ (2012). CYP1A1 $Ile^{462}Val$polymorphism contributes to lung cancer susceptibility among lung squamous carcinoma and smokers: A meta-analysis. PLoS ONE, 7, 43397. https://doi.org/10.1371/journal.pone.0043397
  15. Lee KM, Kang D, Clapper ML, et al (2008). CYP1A1, GSTM1, and GSTT1 polymorphisms, smoking, and lung cancer risk in a pooled analysis among asian populations. Cancer Epidemiol Biomarkers Prev, 17, 1120-6. https://doi.org/10.1158/1055-9965.EPI-07-2786
  16. Lopez-beltran A, Cheng L, Mazzucchelli R, et al (2008). Morphological and molecular profiles and pathways in bladder neoplasms. Anticancer Res, 28, 2893-900.
  17. Pollard C, Smith SC, Theodorescu D (2010). Molecular genesis of non-muscle-invasive urothelial carcinoma (NMIUC). Expert Rev Mol Med, 12, 10. https://doi.org/10.1017/S1462399410001407
  18. Rebbeck TR, Walker AH, Jaffe JM, et al (1999). Glutathione S-transferase-$\mu$ (GSTM1) and -$\Theta$ (GSTT1) genotypes in the etiology of prostate cancer. Cancer Epidemiol Biomarkers Prev, 8, 283-7.
  19. Salinas-Sanchez AS, Donate-Moreno MJ, Lopez-Garrido MP, Gimenez-Bachs JM, Escribano J (2012). Role of CYP1B1 gene polymorphisms in bladder cancer cusceptibility. J Urol, 187, 700-6. https://doi.org/10.1016/j.juro.2011.10.063
  20. Senthilkumar KP, Thirumurugan R (2012). GSTM1 and GSTT1 allele frequencies among various Indian and non-Indian ethnic groups. Asian Pac J Cancer Prev, 13, 6263-7. https://doi.org/10.7314/APJCP.2012.13.12.6263
  21. Sharma A, Pandey A, Sardana S, et al (2012). Genetic polymorphisms of GSTM1 and GSTT1 genes in Delhi and comparison with other Indian and global populations. Asian Pac J Cancer Prev, 13, 5647-52. https://doi.org/10.7314/APJCP.2012.13.11.5647
  22. Shukla D, Dinesh KA, Hallikerimath S, Vivekanandhan S, Venkatakanthaiah Y (2012). Genetic polymorphism of drug metabolizing enzymes (GSTM1 and CYP1A1) as risk factors for oral premalignant lesions and oral cancer. Biomedical Papers, 156, 253-9. https://doi.org/10.5507/bp.2012.013
  23. Song DK, Xing DL, Zhang LR, et al (2009). Association of NAT2, GSTM1, GSTT1, CYP2A6, and CYP2A13 gene polymorphisms with susceptibility and clinicopathologic characteristics of bladder cancer in central China. Cancer Detection and Prev, 32, 416-23. https://doi.org/10.1016/j.cdp.2009.02.003
  24. Tanaka Y, Sasaki M, Kaneuchi M, et al (2002). Polymorphisms of the CYP1B1 gene have higher risk for prostate cancer. Biochem Biophys Res Commun, 296, 820-6. https://doi.org/10.1016/S0006-291X(02)02004-1
  25. Toruner GA, Akyerli C, Ucar A, et al (2001). Polymorphisms of glutathione S-transferase genes (GSTM1, GSTP1 and GSTT1) and bladder cancer susceptibility in Turkish population. Arch Toxicol, 75, 459-64.
  26. Turesky RJ, Le Marchand L (2011). Metabolism and biomarkers of heterocyclic aromatic amines in molecular epidemiology studies: lessons learned from aromatic amines. Chem Res Toxicol, 24, 1169-214. https://doi.org/10.1021/tx200135s
  27. Yang CX, Matsuo K, Wang ZM, Tajima K (2005). Phase I/II enzyme gene polymorphisms and esophageal cancer risk: A meta-analysis of the literature. World J Gastroenterol, 11, 2531-8. https://doi.org/10.3748/wjg.v11.i17.2531
  28. Zhou LP, Luan H, Dong XH, et al (2012). Genetic variants of CYP2D6 gene and cancer risk: a HuGE systematic review and meta-analysis. Asian Pac J Cancer Prev, 13, 3165-72. https://doi.org/10.7314/APJCP.2012.13.7.3165

Cited by

  1. Clinical, Cytogenetic and CYP1A1 exon-1 Gene Mutation Analysis of Beedi Workers in Vellore Region, Tamil Nadu vol.14, pp.12, 2013, https://doi.org/10.7314/APJCP.2013.14.12.7555
  2. Gene expression profiling of human alveolar epithelial cells (A549 cells) exposed to atmospheric particulate matter 2.5 (PM2.5) collected from Seoul, Korea vol.10, pp.4, 2014, https://doi.org/10.1007/s13273-014-0040-9
  3. Are Bladder Neoplasms More Aggresive in Patients with a Smoking-related Second Malignancy? vol.15, pp.9, 2014, https://doi.org/10.7314/APJCP.2014.15.9.4025
  4. Lack of Association Between CYP1A1 Polymorphisms and Risk of Bladder Cancer: a Meta-analysis vol.15, pp.9, 2014, https://doi.org/10.7314/APJCP.2014.15.9.4071
  5. Toxicogenetic Profile and Cancer Risk in Lebanese vol.17, pp.2, 2014, https://doi.org/10.1080/10937404.2013.878679
  6. The CYP1B1 Leu432Val polymorphism and risk of urinary system cancers vol.35, pp.5, 2014, https://doi.org/10.1007/s13277-014-1617-6
  7. RETRACTED ARTICLE: Genetic polymorphisms in the CYP1A1 and CYP1B1 genes and susceptibility to bladder cancer: a meta-analysis vol.41, pp.8, 2014, https://doi.org/10.1007/s11033-014-3359-3
  8. Comparative Tissue Proteomics of Microdissected Specimens Reveals Novel Candidate Biomarkers of Bladder Cancer vol.14, pp.9, 2015, https://doi.org/10.1074/mcp.M115.051524
  9. Leu432Val Polymorphism of CYP1B1 is Not Associated with Squamous Cell Carcinoma of Esophagus - a Case-Control Study from Kashmir, India vol.16, pp.13, 2015, https://doi.org/10.7314/APJCP.2015.16.13.5337
  10. Association between the CYP1B1 polymorphisms and risk of cancer: a meta-analysis vol.290, pp.2, 2015, https://doi.org/10.1007/s00438-014-0946-x
  11. CYP1A1 and GSTP1 gene variations in breast cancer: a systematic review and case–control study vol.15, pp.2, 2016, https://doi.org/10.1007/s10689-015-9849-1
  12. CYP1A1 MspI Polymorphism and Cervical Carcinoma Risk in the Multi-Ethnic Population of Malaysia: a Case-Control Study vol.17, pp.1, 2016, https://doi.org/10.7314/APJCP.2016.17.1.57
  13. Combined Genetic Biomarkers Confer Susceptibility to Risk of Urothelial Bladder Carcinoma in a Saudi Population vol.2017, pp.1875-8630, 2017, https://doi.org/10.1155/2017/1474560
  14. Genetic Polymorphisms and Bladder Cancer Risk: A Meta-Analysis vol.33, pp.3, 2014, https://doi.org/10.1089/dna.2013.2298
  15. genetic variability in Turkish and worldwide populations vol.27, pp.3, 2014, https://doi.org/10.1002/ajhb.22671
  16. The relationship between GSTA1, GSTM1, GSTP1, and GSTT1 genetic polymorphisms and bladder cancer susceptibility vol.95, pp.37, 2016, https://doi.org/10.1097/MD.0000000000004900
  17. Association of Glutathione S-transferase gene polymorphism with bladder Cancer susceptibility vol.18, pp.1, 2018, https://doi.org/10.1186/s12885-018-5014-1
  18. Association of CYP1B1 L432V polymorphism with urinary cancer susceptibility: a meta-analysis vol.9, pp.1, 2014, https://doi.org/10.1186/1746-1596-9-113